Individual [Axis]
Stephan Jackman [Member]
Stephan Jackman 1 [Member]
David J. Katzoff [Member]
David J. Katzoff 1 [Member]
David J. Katzoff 2 [Member]
David J. Katzoff 3 [Member]
David J. Katzoff 4 [Member]
Class of Stock [Axis]
Series B Preferred Stock [Member]
Series C Preferred Stock [Member]
Equity Components [Axis]
Series A Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Sale of Stock [Axis]
At the market [Member]
Antidilutive Securities [Axis]
Equity Option [Member]
Warrant [Member]
Title and Position [Axis]
Directors and Officers Liability Insurance [Member]
Income Tax Authority, Name [Axis]
Federal [Member]
California Franchise Tax Board [Member]
North Carolina [Member]
Other [Member]
Income Tax Jurisdiction [Axis]
Income Tax Jurisdiction, Domestic State and Local [Member]
Income Tax Jurisdiction, Domestic Federal [Member]
Plan Name [Axis]
2016 Stock Incentive Plan [Member]
2021 Stock Incentive Plan [Member]
Award Type [Axis]
Employees And Directors [Member]
Perfromance contingent stock options [Member]
Related and Nonrelated Parties [Axis]
Key employees and director [Member]
Income Statements Location [Axis]
Unamortized stock based compensation [Member]
Stock-based compensation [Member]
Research and development [Member]
General and administrative [Member]
Warrant 2026 [Member]
Warrant 2025 [Member]
Class of Warrant or Right [Axis]
Warrant 1 [Member]
Warrant 2 [Member]
Warrant 3 [Member]
Warrant 4 [Member]
Warrant 5 [Member]
Warrant 6 [Member]
Exercise Price Range [Axis]
8.29 [Member]
108.00 [Member]
4050.00 [Member]
8,437.50 [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Measurement Input Type [Axis]
Measurement Input, Option Volatility [Member]
Measurement Input, Risk Free Interest Rate [Member]
Measurement Input, Expected Dividend Rate [Member]
Product and Service [Axis]
A L001 License [Member]
Guaranteed Insurance Contract, Type of Guarantee [Axis]
First Anniversary [Member]
Second Anniversary [Member]
Third Anniversary [Member]
ALZN002 License [Member]
Additional A L001 License [Member]
License Events [Axis]
Pre-IND Meeting [Member]
IND application filing [Member]
Upon first dosing of patient in a clinical trial [Member]
Upon completion of first clinical trial [Member]
Upon first patient treated in a Phase III clinical trial [Member]
Upon FDA NDA approval [Member]
Upon IND application [Member]
Upon first dosing of patient in first Phase I clinical trial [Member]
Upon completion of first Phase IIB clinical triall [Member]
Upon first patient treated in a Phase III clinical trial [Member]
Upon first commercial sale [Member]
First commercial sale [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Securities Purchase Agreements [Member]
Legal Entity [Axis]
Ault Lending [Member]
Orchid Finance [Member]
October 2024 ATM [Member]
March 2026 ATM [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
ICFR Auditor Attestation Flag
Document Financial Statement Error Correction [Flag]
Auditor Firm ID
Auditor Name
Auditor Location
Statement [Table]
Statement [Line Items]
ASSETS
CURRENT ASSETS
Cash
Prepaid expenses and other current assets
TOTAL CURRENT ASSETS
Property, plant and equipment, net
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable and accrued liabilities
TOTAL LIABILITIES, ALL CURRENT
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY
Preferred Stock, Value
Common stock, $0.0001 par value: 300,000,000 shares authorized; 4,256,039 and 778,733 issued and outstanding as of April 30, 2026 and 2025, respectively
Additional paid-in capital
Accumulated deficit
TOTAL STOCKHOLDERS’ EQUITY
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
Preferred stock, par value (in dollars per share)
Preferred stock shares designated
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in dollars per share)
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
OPERATING EXPENSES
Research and development
General and administrative
Total operating expenses
Loss from operations
OTHER EXPENSE, NET
Interest income
Interest expense
Total other expense, net
NET LOSS
Dividends on preferred shares
Deemed dividend on warrant modification issued with preferred shares
NET LOSS AVAILABLE TO COMMON SHARES
Basic net loss per common share
Diluted net loss per common share
Basic weighted average common shares outstanding
Diluted weighted average common shares outstanding
Beginning balance, value
Beginning balance, shares
Issuance of common stock for cash, net of issuance costs
Issuance of common stock for cash, net of issuance costs, shares
Issuance of common stock for restricted stock awards
Issuance of common stock for restricted stock awards, shares
Issuance of preferred stock for cash, net of issuance costs
Issuance of preferred stock for cash, net of issuance costs, shares
Proceeds from stock option exercise
Proceeds from stock option exercise,shares
Conversion of preferred stock to common stock
Conversion of preferred stock to common stock, shares
Stock-based compensation to employees, directors and consultants
Conversion of note payable and interest to Series A preferred stock
Exchange of series A preferred stock to series C preferred stock
Exchange of series A preferred stock to series C preferred stock, shares
Stock-based compensation to employees and consultants
Preferred dividends
Preferred dividends, shares
Net loss
Ending balance, value
Ending balance, shares
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
Interest expense - debt discount
Stock-based compensation to employees, directors and consultants
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Accounts payable and accrued liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchase of equipment
Net cash used in investing activities
Cash flows from financing activities:
Net proceeds from the issuance of common stock
Proceeds from stock option exercise
Net proceeds from the issuance of preferred stock
Net cash provided by financing activities
Net (decrease) increase in cash
Cash at beginning of period
Cash at end of period
Supplemental disclosures of cash flow information:
Non-cash financing activities:
Conversion of Series A convertible preferred stock to common stock
Conversion of Series B convertible preferred stock to common stock
Conversion of Series C convertible preferred stock to common stock
Fair value of warrants issued in connection with Series A convertible preferred stock
Preferred stock dividends
Conversion of note payable and accrued interest into Series A convertible preferred stock
Exchange of Series A convertible preferred stock into Series C convertible preferred stock
Fair value of warrants issued with preferred stock
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Cybersecurity Risk Management Processes Integrated [Flag]
Cybersecurity Risk Management Processes Integrated [Text Block]
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
Cybersecurity Risk Board of Directors Oversight [Text Block]
Cybersecurity Risk Role of Management [Text Block]
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted [Flag]
Non-Rule 10b5-1 Arrangement Adopted [Flag]
Rule 10b5-1 Arrangement Terminated [Flag]
Non-Rule 10b5-1 Arrangement Terminated [Flag]
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted [Flag]
Awards Close in Time to MNPI Disclosures [Table]
Award Timing Method [Text Block]
Award Timing, How MNPI Considered [Text Block]
MNPI Disclosure Timed for Compensation Value [Flag]
Awards Close in Time to MNPI Disclosures [Table Text Block]
Awards Close in Time to MNPI Disclosures, Individual Name
Award Underlying Securities Amount
Award Exercise Price
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY, GOING CONCERN AND MANAGEMENT’S PLANS
SIGNIFICANT ACCOUNTING POLICIES
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS
Income Tax Disclosure [Abstract]
INCOME TAXES
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION
Warrants
WARRANTS
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Equity [Abstract]
EQUITY TRANSACTIONS
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Basis of Presentation
Accounting Estimates
Cash and Cash Equivalents
Fair Value of Financial Instruments
Income Taxes
Stock-Based Compensation
Warrants
Loss per Common Share
Preferred Stock Classification
Segment Reporting
Recent Accounting Standards
Schedule of anti-dilutive securities excluded from computation of earnings per share
Schedule of prepaid expenses and other current assets
Schedule of loss before provision for income taxes
Schedule of deferred tax assets and liabilities
Schedule of effective income tax rate reconciliation
Schedule of amounts of cash income taxes paid
Schedule of share-based payment arrangement, option, activity
Schedule of estimated fair value of stock options granted
Schedule of stock-based compensation
Schedule of Common Stock
Schedule of common stock warrants outstanding
Schedule of warrant activity
Schedule of assumptions used
Schedule of contractual obligation, fiscal year maturity
Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]
Subsidiary, Sale of Stock [Line Items]
Cash
Accumulated deficit
Net loss
Cash used in operating activities
Number of common stock sold
Proceeds from offering
Stockholders' equity
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount
Cash equivalents
Prepaid clinical trial expenses
Prepaid insurance
Other prepaid expenses
Total prepaid expenses and other current assets
Insurance purchased
Pre-tax loss:
Federal
Total pre-tax loss
Deferred income tax asset:
Accruals
Capitalized research expenditures
Net operating loss carryover
Stock-based compensation
Total deferred tax asset
Fixed assets
Valuation allowance
Deferred income tax asset, net of allowance
U.S. Federal statutory tax rate, amount
Tax benefit at U.S. Federal statutory tax rate
State and local income tax, net of federal income tax effect, amount
State income tax, net of federal benefit
Change in valuation allowance, amount
Change in valuation allowance
Stock-based compensation
Other
Nontaxable / Nondeductible Items, Other, amount
Nontaxable / Nondeductible Items, Other, percent
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Total provision for income taxes, amount
Effective tax rate
Operating Loss Carryforwards [Table]
Operating Loss Carryforwards [Line Items]
Income taxes paid
Foreign
Other
Income taxes, net of amounts refunded
Effective Income Tax Rate Reconciliation [Table]
Effective Income Tax Rate Reconciliation [Line Items]
Valuation allowance
Operating loss carryforwards
Uncertain tax positions
Interest or penalties
Shares available for grant begining (in shares)
Number of shares begining (in shares)
Weighted average exercise price begining (in dollars per share)
Weighted average remaining contractual life begining (years)
Aggregate intrinsic value begining
Shares available for grant, options granted
Number of shares, options granted
Weighted average exercise price, options granted
Weighted average remaining contractual life, granted
Aggregate intrinsic value, options exercisable at end
Shares available for grant, options exercised
Number of shares, options exercised
Shares available for grant, options expired
Number of shares, options expired
Weighted average exercise price, options exercised
Shares available for grant end (in shares)
Number of shares end (in shares)
Weighted average exercise price end (in dollars per share)
Weighted average remaining contractual life end (years)
Aggregate intrinsic value end
Number of shares, options vested and expected to vest at end
Weighted average exercise price, options vested and expected to vest at end
Weighted average remaining contractual life, options vested and expected to vest at end
Aggregate intrinsic value, options vested and expected to vest at end
Number of shares, options exercisable at end
Weighted average exercise price, options exercisable at end
Weighted average remaining contractual life, options exercisable at end
Aggregate intrinsic value, options exercisable at end
Expected term (in years)
Volatility
Risk-free interest rate
Dividend yield
IncomeStatementsLocationAxis [Axis]
Total
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized
Share-based compensation additional shares authorized
Share-based compensation arrangement by share-based payment award, expiration period
Stock options granted to employees and consultants
Options granted
Terms of award
Unamortized stock-based compensation expense related to unvested employee and non-employee awards
Weighted-average period
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Issuance Date
Quantity
Exercise price
Original Expiration
Fair Value at Date of Grant
Share-Based Payment Arrangement, Option, Exercise Price Range [Table]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercse price (in dollars per share)
Number Outstanding
Weighted average remaining contractual life (years)
Warrant outstanding, weighted average exercise price (in dollars per share)
Number of warrant exercisable
Warrant exercisable, weighted average exercise price (in dollars per share)
Warrant Outstanding at beginning
Weighted Average Exercise Price, at beginning
Warrant Cancelled/Expired
Weighted Average Exercise Price,
Warrant Outstanding at ending
Weighted Average Exercise Price, at end
Expected term (in years)
Warrants measurement input
Aggregate number of stock repurchase
Exercise price (in dollars per share)
Product Liability Contingency [Table]
Product Liability Contingency [Line Items]
Payment
Due date
Percentage of royalty payments on net sales of product
Description of licenses agreements
Initial license fees
Payments for royalties
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Preferred stock, shares authorized
Number of shares purchase
Termination loans description
Number of warrants purchase
Sale of stock, net proceeds
Sale of stock, number of shares issued
Cancellations of cash advances
Converted shares
Number of shares issued
Fair market value of warrants
Subsequent Event [Table]
Subsequent Event [Line Items]
Proceeds from sale of stock
The element represents stock incentive plan2016 member.
The element represents perfromance contingent stock options member.
The element represents key employees and director member.
The element represents unamortized stock based compensation member.
The element represents aggregate number of stock repurchase.
The element represents sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term.
The element represents percentage of royalty payments on net sales of product..
The element represents a l001 license member.
The element represents description of licenses agreements.
Amount of initial license fees.
The element represents additional a l001 license member.
The element represents license events axis.
The element represents pre ind meeting member.
The element represents ind application filing member.
The element represents upon first dosing of patient in clinical trial member.
The element represents upon completion of first clinical trial member.
The element represents exercise price1 member.
The element represents exercise price2 member.
The element represents exercise price3 member.
The element represents exercise price4 member.
The element represents class of warrant or right weighted average exercise price of warrants or rights.
The element represents class of warrant or right exercisable.
The element represents class of warrant or right exercisable weighted average exercise price.
The element represents number of shares purchase.
The element represents securities purchase agreements member.
Upon first patient treated in a Phase III clinical trial [Member] [Default Label]
Assets, Current
Assets
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Interest Expense, Operating and Nonoperating
Nonoperating Income (Expense)
DeemedDividendOnWarrantMedicationIssuedWithPreferred
Net Income (Loss) Available to Common Stockholders, Basic
Equity, Including Portion Attributable to Noncontrolling Interest
Shares, Outstanding
Share-Based Payment Arrangement, Noncash Expense
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Machinery and Equipment
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Proceeds from Stock Options Exercised
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Commitments and Contingencies Disclosure [Text Block]
WarrantsPolicyTextBlock
Cash [Default Label]
Retained Earnings, Appropriated
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Prepaid Expense and Other Assets
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Deferred Tax Assets, Gross
Deferred Tax Liabilities, Property, Plant and Equipment
StockCompensationRate
IncomeTaxesPaidOther
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
WarrantExpectedTerm